Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.
Herold
M
M
HELIOS - Klinikum Erfurt, 2. Medizinische Klinik, Department of Hematology/Oncology, Nordhäuserstrasse 74, Germany. miherold@erfurt.helios-kliniken.de
Dölken
G
G
Fiedler
F
F
Franke
A
A
Freund
M
M
Helbig
W
W
Pasold
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000633:toxicity; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000633:toxicity; D002699:Chlorambucil / Q000008:administration & dosage; D002985:Clinical Protocols; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D018579:Patient Selection; D011239:Prednisolone / Q000008:administration & dosage; D011446:Prospective Studies; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D002699:Chlorambucil; D000069283:Rituximab; D011239:Prednisolone; D008942:Mitoxantrone